Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

ClinicalTrials.gov ID: NCT04546581

Public ClinicalTrials.gov record NCT04546581. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 10, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This protocol will serve as a platform for assessing treatments for adult patients hospitalized for medical management of COVID-19 without related serious end-organ failure. Trials will involve sites around the world strategically chosen to ensure rapid enrollment. This trial will compare hyperimmune intravenous immunoglobulin (hIVIG) with matched placebo, when added to standard of care (SOC), for preventing further disease progression and mortality related to COVID-19. SOC will include remdesivir unless it is contraindicated for an individual patient.

Study identification

NCT ID
NCT04546581
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
University of Minnesota
Other
Enrollment
593 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 7, 2020
Primary completion
May 20, 2021
Completion
May 20, 2021
Last update posted
Apr 3, 2022

2020 – 2021

United States locations

U.S. sites
18
U.S. states
11
U.S. cities
16
Facility City State ZIP Site status
Penrose Hospital Colorado Springs Colorado 80907
St. Francis Health Services Colorado Springs Colorado 80907
St. Anthony Hospital Lakewood Colorado 80228
Saint Anthony North Health Campus Westminster Colorado 80023
Washington VA Medical Center Washington D.C. District of Columbia 20422
Redmond Regional Medical Center Rome Georgia 30165
National Institutes of Health Clinical Center Bethesda Maryland 20892
University of Massachusetts Worcester Massachusetts 01665
Hennepin Healthcare Research Institute/HCMC Minneapolis Minnesota 55415
University of Missouri Columbia Missouri 65212
Cox Medical Centers Springfield Missouri 65807
FirstHealth Moore Regional Hospital Pinehurst North Carolina 28394
Ohio Health Research Institute Columbus Ohio 43215
Hendrick Medical Center Abilene Texas 79601
CHRISTUS Spohn Shoreline Hospital Corpus Christi Texas 78404
University of Texas Southwestern Medical Center Dallas Texas 75235
CJW Chippenham Medical Center Richmond Virginia 23225
Henrico Doctors' Hospital (HCA) Richmond Virginia 23229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04546581, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 3, 2022 · Synced Sep 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04546581 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →